Aktie A065170 BL PHARMTECH CORP.
Zu einer Liste hinzufügen
Um diese Funktionalität nutzen zu können, müssen Sie Mitglied sein
EinloggenRegistrieren

Andere Sprachen BL Pharmtech Corp.

Aktien

A065170

KR7065170003

A065170

Schlusskurs Korea S.E.
Andere Börsenplätze
 00:00:00 18.04.2024 		% 5 Tage % 1. Jan.
473 KRW +3.28% Intraday Chart für BL Pharmtech Corp. +1.07% -6.34%
28.03. Youngchul Park hat die Übernahme von 24,43% der Anteile an der BL Pharmtech Corp. (KOSDAQ : A065170) von der Bioleaders Corporation (KOSDAQ:A142760) abgeschlossen. CI
20.03. BL Pharmtech Corp. meldet Ergebnis für das am 31. Dezember 2023 endende Geschäftsjahr CI

Andere Sprachen

Suchen
Ergebnisse ansehen
Erhalten Sie Zugang zu allen Nachrichten über alle Unternehmen: Verpassen Sie keine profitable Anlagechance mehr!
100% kostenlose Registrierung
Youngchul Park completed the acquisition of 24.43% stake in BL Pharmtech Corp. (KOSDAQ : A065170) from Bioleaders Corporation.
BL Pharmtech Corp. Reports Earnings Results for the Full Year Ended December 31, 2023
Youngchul Park agreed to acquire 24.43% stake in BL Pharmtech Corp. (KOSDAQ : A065170) from Bioleaders Corporation for KRW 9.3 billion.
BL Pharmtech agreed to acquire an additional 30.89% stake in Anyone F&C Co., Ltd. for KRW 9 billion
Kwang Dong Pharmaceutical Co., Ltd. agreed to acquire a 58.73% stake in BL Healthcare Corp. from BL Healthcare Corp. for KRW 30 billion
BL Pharmtech Corp. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023
BL Pharmtech Corp. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023
BL Pharmtech Corp. Reports Earnings Results for the First Quarter Ended March 31, 2023
Next Bt Co., Ltd. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2022
Next Bt Co., Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2022
Next Bt Co., Ltd. Reports Earnings Results for the Full Year Ended December 31, 2021
Next Bt Co., Ltd. announced that it has received KRW 6 billion in funding from Bioleaders Corporation, Dk Life Science Co., Ltd. and other investors
Next Bt Co., Ltd. announced that it expects to receive KRW 6 billion in funding from Bioleaders Corporation, Dk Life Science Co., Ltd. and other investors
Next Bt Co., Ltd. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2021
Next Bt Co., Ltd. announced that it has received KRW 10.4 billion in funding from Samsung Securities Co., Ltd., KB Securities Co., Ltd., NH Investment & Securities Co., Ltd., Korea Investment & Securities Co., Ltd., Mirae Asset Venture Investment Co., Ltd., Mirae Asset Securities Co., Ltd.
Next Bt Co., Ltd. announced that it expects to receive KRW 10.4 billion in funding from Samsung Securities Co., Ltd., KB Securities Co., Ltd., NH Investment & Securities Co., Ltd., Korea Investment & Securities Co., Ltd., Mirae Asset Venture Investment Co., Ltd., Mirae Asset Securities Co., Ltd.
Next Bt Co., Ltd. completed the acquisition of the remaining 77.7% stake in TCM Biosciences Inc..
Next Bt Co., Ltd. agreed to acquire the remaining 77.7% stake in TCM Biosciences Inc. for KRW 37 billion.
Next Bt Co., Ltd. acquired 22.25% stake in TCM Biosciences Inc. from Park Young Chul for KRW 15.9 billion.
Next Bt Co., Ltd. announced that it has received KRW 6.5 billion in funding
Keine Ergebnisse zu dieser Suche
Alle Nachrichten Analystenempfehlungen Wichtige Fakten Insiders Transkripte Pressemitteilungen Offizielle Publikationen Andere Sprachen Trading-Ideen MarketScreener Artikel MarketScreener Analysen

Filter

Suchen

Datum der Veröffentlichung

Vom

Bis

  1. Börse
  2. Aktien
  3. A065170 Aktie
  4. Nachrichten BL Pharmtech Corp.
  5. Andere Sprachen